VLP VACCINES FOR HIV PREVENTION
用于预防 HIV 的 VLP 疫苗
基本信息
- 批准号:8357486
- 负责人:
- 金额:$ 7.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAdjuvantAntibody FormationAntigen PresentationAntigen-Presenting CellsAntigensDoseFlagellinFundingGrantHIVHIV Envelope Protein gp120HIV vaccineHIV-1HumanImmunityImmunoglobulin Variable RegionInfectionMacacaMembraneNational Center for Research ResourcesParticulatePrimatesPrincipal InvestigatorProcessResearchResearch InfrastructureResourcesSourceStructureTestingUnited States National Institutes of HealthVaccine AntigenVaccinesVirionVirus-like particlecostdesignenv Gene Productsneutralizing antibodynovelnovel strategiesnovel vaccinesprophylacticresponsesimian human immunodeficiency virus
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
A prophylactic HIV-1 vaccine should elicit broadly cross-reactive neutralizing activity. The gp120-gp41 Env protein on the native virion is the primary target for eliciting neutralizing antibodies. Although several features of Env make it difficult to elicit broadly neutralizing antibodies, progress has been achieved in recent years in enhancing the immunity of Env by modifying its structure, employing novel delivery platforms, and co-administration of adjuvants.
The use of virus-like particles (VLPs) has shown great potential as a new vaccine platform. Recent studies have also demonstrated that lower titers of neutralizing antibody can protect against low-dose repeated mucosal SHIV challenge in macaques, which mimics infection of humans by sexual contact.
Recently we developed novel approaches to produce Env-enriched chimeric HIV VLPs (cVLPs) and found that such cVLPs containing a membrane-anchored form of flagellin or a variable-region truncated flagellin as adjuvants induced high levels of systemic and mucosal HIV specific antibody responses, with broadened neutralizing activity. Our research is testing the hypothesis that the presence of antigen and adjuvant in the same particulate structure will generate an effective HIV vaccine antigen, by delivering both components simultaneously to the same antigen-presenting cells.
The combination of Env antigen presentation in its native state combined with a membrane-anchored adjuvant and mucosal delivery provides a promising approach to stimulate strong nAb response against HIV, designed to block the initial step in the infection process.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。
预防性HIV-1疫苗应引起广泛的交叉反应中和活性。天然病毒体上的gp 120-gp 41 Env蛋白是引发中和抗体的主要靶标。尽管Env的几个特征使得难以引发广泛中和抗体,但近年来在通过修饰其结构、采用新型递送平台和共施用佐剂来增强Env的免疫性方面取得了进展。
病毒样颗粒(VLP)的使用已显示出作为新疫苗平台的巨大潜力。最近的研究还表明,较低滴度的中和抗体可以保护猕猴免受低剂量重复粘膜SHIV攻击,其模拟通过性接触感染人类。
最近,我们开发了新的方法来生产Env富集的嵌合HIV VLP(cVLP),并发现这种cVLP含有膜锚定形式的鞭毛蛋白或可变区截短的鞭毛蛋白作为佐剂诱导高水平的全身和粘膜HIV特异性抗体应答,具有扩大的中和活性。我们的研究正在测试这样一种假设,即抗原和佐剂在同一颗粒结构中的存在将通过将两种组分同时递送到相同的抗原呈递细胞来产生有效的HIV疫苗抗原。
Env抗原在其天然状态下的呈递与膜锚定佐剂和粘膜递送的组合提供了一种有希望的方法来刺激针对HIV的强nAb应答,其设计用于阻断感染过程中的初始步骤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD W COMPANS其他文献
RICHARD W COMPANS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD W COMPANS', 18)}}的其他基金
Skin Vaccination Against Influenza in the Young And Aged
年轻人和老年人的流感皮肤疫苗接种
- 批准号:
9210049 - 财政年份:2015
- 资助金额:
$ 7.43万 - 项目类别:
Skin Vaccination Against Influenza in the Young And Aged
年轻人和老年人的流感皮肤疫苗接种
- 批准号:
8886505 - 财政年份:2015
- 资助金额:
$ 7.43万 - 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
- 批准号:
8257884 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
- 批准号:
8650780 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
- 批准号:
8463750 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC)
流感发病机制
- 批准号:
8357468 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
- 批准号:
8076663 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
- 批准号:
8837557 - 财政年份:2011
- 资助金额:
$ 7.43万 - 项目类别:
Design of HIV VLPs with Enhanced Immunogenicity
具有增强免疫原性的 HIV VLP 的设计
- 批准号:
8278665 - 财政年份:2010
- 资助金额:
$ 7.43万 - 项目类别:
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC)
流感发病机制
- 批准号:
8172422 - 财政年份:2010
- 资助金额:
$ 7.43万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 7.43万 - 项目类别: